BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 19, 2025
Home » Topics » Science » Nanotechnology

Nanotechnology
Nanotechnology RSS Feed RSS

Cross section of brain
Neurology/psychiatric

Nanobody inhibiting complement in the brain protects mice from progressive MS

Sep. 23, 2024
Investigators from Abzyme Therapeutics LLC have hypothesized that inhibiting this pathway in the CNS may prevent tissue damage and cease the progression of multiple sclerosis (MS).
Read More
3D concept image of nanoparticle layers
Immuno-oncology

Intravesical instillation of CRISPR-Cas13a and fenbendazole nanoparticle formulations shows synergy in bladder cancer model

Aug. 29, 2024
Researchers from Shenzhen University and affiliated organizations detailed the preclinical characterization of a synergistic intravesical instillation of fenbendazole (FBZ) and CRISPR-Cas13a-based nanoplatform as a new strategy for the treatment of bladder cancer.
Read More
Photomicrograph of fine needle aspiration cytology of a pulmonary nodule showing adenocarcinoma, a type of non-small-cell carcinoma.
Immuno-oncology

Triple nanotherapy could benefit more lung cancer patients

June 20, 2024
By Mar de Miguel
A new approach against non-small-cell lung cancer (NSCLC) has combined immunotherapy with molecularly targeted therapy to activate the immune response and inhibit oncogenic pathways, which prevented tumor progression and eliminated cancer cells. Brigham and Women’s Hospital scientists have developed nanoparticles loaded with antibody conjugates that could deliver large amounts of treatment to the tumor tissue. This new strategy could improve the results of conventional immunotherapy in these patients and reduce toxicity of existing treatments.
Read More
AI-generated image for cancer cells observed under a microscope
Immuno-oncology

Shaperon signs MOU with Dong-A ST to accelerate development of nanobody-based drugs

June 11, 2024
Hudson Therapeutics Inc., a U.S. subsidiary of Shaperon Inc., has announced the signing of a memorandum of understanding (MOU) between Shaperon and Dong-A ST Co. Ltd. for the development of nanobody-based new drugs.
Read More
Cancer cells
Immuno-oncology

Cancervax reports milestone in development of universal cancer vaccine

May 21, 2024
Cancervax Inc. has announced that its University of California, Los Angeles (UCLA) research team has achieved a critical milestone by creating a process to add any antibody to lipid nanoparticles (LNPs) using click chemistry, for targeting cancer cells.
Read More
Pregnancy
Obstetrics

Aska Pharmaceutical partners with Red Arrow Therapeutics on new preeclampsia treatment

March 19, 2024
Aska Pharmaceutical Co. Ltd., a subsidiary of Aska Pharmaceutical Holdings Co. Ltd., and Red Arrow Therapeutics Inc. have signed a joint research agreement to develop a new treatment for preeclampsia using advanced nanotechnology.
Read More
Cancer

N4 Pharma offers update on Nuvec-based siRNA in vitro studies

Feb. 16, 2024
N4 Pharma plc has offered an update on its ongoing in vitro siRNA research work, using its Nuvec silica nanoparticle delivery system.
Read More
Accumulation of nanorobots in a bladder tumor by microscopy.
Drug Design, Drug Delivery & Technologies

Self-propelled nanobots can deliver drugs to bladder, other tumors

Jan. 29, 2024
By Coia Dulsat
Researchers from the Institute for Bioengineering of Catalonia (IBEC) and collaborators have successfully treated bladder tumors in mice using urease-powered nanobots. The testing consisted of the administration of 18F-nanorobots to tumor-bearing mice divided into four groups depending on tumor volumes using a group of non-tumor-bearing mice as control. Importantly, the therapy remained in the bladder with only a very small proportion of radioactivity seen in other organs. The results were published in Nature Nanotechnology on Jan. 15, 2024.
Read More
Drug Design, Drug Delivery & Technologies

Genedit and Genentech collaborate on nanoparticle delivery for nucleic acid-based medicines

Jan. 26, 2024
Genedit Inc. has entered into a multiyear collaboration and license agreement with Genentech Inc., a member of the Roche Group, to use Genedit's Nanogalaxy platform to discover and develop novel hydrophilic nanoparticles to deliver Genentech's nucleic acid-based medicines for treatment of autoimmune disease.
Read More
Nobel Prize graphic with illustrations of Moungi Bawendi, Louis Brus and Alexei Ekimov
Drug Design, Drug Delivery & Technologies

Nobel Prize in Chemistry 2023 goes to quantum dots, which illuminated the path to nanotechnology

Oct. 4, 2023
By Mar de Miguel
Quantum dots, a phenomenon in quantum physics that alters the energy of electrons and changes the properties of particles, caught the attention of the Royal Swedish Academy of Sciences (KVA) for the 2023 Nobel Prize in Chemistry.
Read More
Previous 1 2 3 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing